GlassScriptPhysician profile
Scott C Lindsay
NPI 1730389206
$1,452.74
in general payments reported to CMS, 2019-2025
13 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.41 · 2020: $182 · 2021: $439 · 2022: $13.56 · 2023: $427 · 2024: $227 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $799.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $552.75 | 2020-2025 | |
| Allergan, INC. | $319.13 | 2021 | |
| Janssen Biotech, INC. | $137.56 | 2023 | Tremfya |
| Sientra, INC. | $119.61 | 2021 | |
| Motiva USA, LLC | $88.75 | 2025 | |
| Revance Therapeutics, INC. | $78.11 | 2024 | Daxxify |
| Kci USA, INC. | $40.12 | 2020 | |
| Leo Pharma INC. | $26.52 | 2020 | |
| Almirall LLC | $20.78 | 2020 | |
| Mayne Pharma Commercial LLC | $20.01 | 2020 | |
| Tepha INC | $19.41 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.43 | 2023 | Exparel |
| Integra Lifesciences Corporation | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lindsay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.